THE ROLE OF GENOMIC SCREENING IN TRANSFORMING PUBLIC HEALTH Understanding ethical, legal & social impacts of genomic screening
With
Dr Jane Tiller, Ethical, Legal & Social Adviser,
Public Health Genomics, Monash University
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | July 2025
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
Jane also focusses on identifying and addressing the ethical, legal and social barriers to public acceptability and uptake of genetic screening. She co-founded the Australian Genetic Non-Discrimination Working Group, and led a project from 2020-2023 about genetic discrimination in life insurance. Jane led significant advocacy efforts towards translating her research findings into real world policy change. She was instrumental in the Government’s 2024 announcement that it will legislate a total ban on the use of genetic results in life insurance underwriting. Jane’s work has been recognised through a number of competitive awards, including recently the prestigious 2024 Research Australia Advocacy Award.
Source: Supplied
-
WA and QLD RSV Immunisation programs show drops in infant hospitalisations
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.
-
SAHMRI Celebrates 10 Years of Research
SAHMRI represents an exciting and unique statewide concept, bringing together basic and translational research, South Australia’s three universities and the health system. SAHMRI works in collaboration with its partners to provide a clear focal point for health and medical research, including paving the way for new partnerships, innovative research projects and improved health outcomes.
Executive Director, Professor Maria Makrides spoke to Australian Health Journal about 3 achievements in the past 10 years that have had significant impact
International leadership breakthroughs in leukaemia research
Culturally appropriate Indigenous health research and clinical care
Omega 3 fatty acids as a preterm birth prevention -
Ensuring stringent quality standards in the lifecycle of medical devices
Dr Jasjit Baveja is the Associate Director of Policy at the Medical Technology Association of Australia (MTAA), where she oversees regulatory affairs, clinical code of practice, procurement, industry policy, reimbursement, and advocacy. With over 20 years of experience in the medical device regulatory space, Dr Bavej’s expertise lies in providing educational opportunities for regulatory professionals in Australia to ensure continuous learning and professional development. She collaborates closely with the Therapeutic Goods Administration (TGA) to run workshops that provide invaluable experience, networking opportunities, and skill enhancement.
